FOLH1 and cancer: With the exception of prostate adenocarcinoma (PRAD), liver hepatocellular carcinoma (LIHC), and the aforementioned uterine and kidney cancer types, all remaining cancer types showed lower expression in the salivary gland and liver, and among solid tumors, uveal melanoma (UVM), rectal adenocarcinoma (READ), and thymomas (THYM) had lower expression of FOLH1 in the tumor relative to the spleen (Figure 4A, Supplementary Table S1).